{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:51Z","timestamp":1707524211728},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,3]]},"DOI":"10.7759\/cureus.13663","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T09:10:16Z","timestamp":1614762616000},"source":"Crossref","is-referenced-by-count":1,"title":["An Observational Study to Evaluate the Effectiveness of Rivaroxaban in the Management of Cerebral Venous Sinus Thrombosis"],"prefix":"10.7759","author":[{"given":"Meraj","family":"Fatima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saira","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Iltaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijaz","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/2396987317719364","article-title":"European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology","volume":"2","author":"Ferro JM","year":"2017","unstructured":"Ferro JM, Bousser MG, Canh\u00e3o P, et al.. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur Stroke J. 2017, 2:195-221. 10.1177\/2396987317719364","journal-title":"Eur Stroke J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4172\/2254-609X.100031","article-title":"Treatment of cerebral venous thrombosis with rivaroxaban","volume":"5","author":"Anticoli S","year":"2016","unstructured":"Anticoli S, Pezzella FR, Scifoni G, Ferrari C, Pozzessere C. Treatment of cerebral venous thrombosis with rivaroxaban. J Biomed Sci. 2016, 5:1-2. 10.4172\/2254-609X.100031","journal-title":"J Biomed Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4589","article-title":"The role of warfarin and rivaroxaban in the treatment of cerebral venous thrombosis","volume":"11","author":"Fayyaz M","year":"2019","unstructured":"Fayyaz M, Abbas F, Kashif T. The role of warfarin and rivaroxaban in the treatment of cerebral venous thrombosis. Cureus. 2019, 11:e4589. 10.7759\/cureus.4589","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1022-8","article-title":"Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol","volume":"8","author":"Bose G","year":"2019","unstructured":"Bose G, Graveline J, Yogendrakumar V, Fergusson D, Dowlatshah D. Direct oral anticoagulants in treatment of cerebral venous thrombosis: a systematic review protocol. Syst Rev. 2019, 8:99. 10.1186\/s13643-019-1022-8","journal-title":"Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.006167","article-title":"Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis first experience in 7 patients","volume":"45","author":"Geisb\u00fcsch C","year":"2014","unstructured":"Geisb\u00fcsch C, Richter D, Herweh C, Ringleb PA, Nagel S. Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis first experience in 7 patients. Stroke. 2014, 45:2469-2471. 10.1161\/STROKEAHA.114.006167","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.5045","article-title":"Cerebral venous thromboembolism in antiphospholipid syndrome successfully treated with the combined use of an anti-Xa inhibitor and corticosteroid","volume":"54","author":"Sugie M","year":"2015","unstructured":"Sugie M, Iizuka N, Shimizu Y, Ichikawa H. Cerebral venous thromboembolism in antiphospholipid syndrome successfully treated with the combined use of an anti-Xa inhibitor and corticosteroid. Internal Med. 2015, 54:3051-3056. 10.2169\/internalmedicine.54.5045","journal-title":"Internal Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5114\/amsad.2017.72533","article-title":"Non-hemorrhage-related adverse effects of rivaroxaban","volume":"2","author":"Christopoulou EC","year":"2017","unstructured":"Christopoulou EC, Filippatos TD, Elisaf MS. Non-hemorrhage-related adverse effects of rivaroxaban. Arch Med Sci Atheroscler Dis. 2017, 2:108-112. 10.5114\/amsad.2017.72533","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj YH","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015, 11:967-977. 10.2147\/TCRM.S84210","journal-title":"Ther Clin Risk Manag"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4081\/itjm.2013.s8.1","article-title":"Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics","volume":"7","author":"Masotti L","year":"2013","unstructured":"Masotti L, Campanini M. Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. Ita J Med. 2013, 7:1-7. 10.4081\/itjm.2013.s8.1","journal-title":"Ita J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.30.3.484","article-title":"Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis","volume":"30","author":"Bruijin S","year":"1999","unstructured":"Bruijin S, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999, 30:484-488. 10.1161\/01.str.30.3.484","journal-title":"Stroke"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000047635","article-title":"Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998","volume":"11","author":"Ferro JM","year":"2001","unstructured":"Ferro JM, Correia M, Pontes C, Baptista MV, Pita F. Cerebral vein and dural sinus thrombosis in Portugal: 1980-1998. Cerebrovasc Dis. 2001, 11:177-182. 10.1159\/000047635","journal-title":"Cerebrovasc Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman S","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, et al.. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009, 361:2342-2352. 10.1056\/NEJMoa0906598","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90607-q","article-title":"Heparin treatment in sinus venous thrombosis","volume":"338","author":"Einhaupl KM","year":"1991","unstructured":"Einhaupl KM, Villringer A, Meister W, et al.. Heparin treatment in sinus venous thrombosis. Lancet. 1991, 338:597-600. 10.1016\/0140-6736(91)90607-q","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2764","article-title":"Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis. A randomized clinical trial","volume":"76","author":"Ferro JM","year":"2019","unstructured":"Ferro JM, Coutinho JM, Dentali F, et al.. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis. A randomized clinical trial. JAMA Neurol. 2019, 76:1457-1465. 10.1001\/jamaneurol.2019.2764","journal-title":"JAMA Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12462","article-title":"Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients","volume":"10","author":"Mendonca MD","year":"2015","unstructured":"Mendonca MD, Barbosa R, Silva VC, Calado S, Baptista MV. Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis: a series of 15 patients. Int J Stroke. 2015, 10:1115-1118. 10.1111\/ijs.12462","journal-title":"Int J Stroke"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000254579.16319.35","article-title":"Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage","volume":"32","author":"Girot M","year":"2007","unstructured":"Girot M, Ferro JM, Canh\u00e3o P, et al.. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke. 2007, 32:337-342. 10.1161\/01.STR.0000254579.16319.35","journal-title":"Stroke"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-014-0523-2","article-title":"Cerebral venous thrombosis: update on diagnosis and treatment","volume":"16","author":"Ferro JM","year":"2014","unstructured":"Ferro JM, Canh\u00e3o P. Cerebral venous thrombosis: update on diagnosis and treatment. Curr Cardiol Rep. 2014, 16:523-533. 10.1007\/s11886-014-0523-2","journal-title":"Curr Cardiol Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927046","article-title":"Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis","volume":"121","author":"Martinelli I","year":"2010","unstructured":"Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci M. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation. 2010, 121:2740-2746. 10.1161\/CIRCULATIONAHA.109.927046","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/53157-an-observational-study-to-evaluate-the-effectiveness-of-rivaroxaban-in-the-management-of-cerebral-venous-sinus-thrombosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:11Z","timestamp":1707507011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/53157-an-observational-study-to-evaluate-the-effectiveness-of-rivaroxaban-in-the-management-of-cerebral-venous-sinus-thrombosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.13663","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,3]]}}}